The Advanced Medical Technology Assn. (AdvaMed) launched a new lobby for the diagnostics industry it’s calling AdvaMed Dx.
The national trade council for the medical device industry said its new division will focus on “issues facing companies that manufacture in vitro diagnostic technologies,” functioning as “an association within an association” with access to AdvaMed‘s resources, according to a press release.
AdvaMed Dx will be governed by an 18-member board of directors, chaired by Beckman Coulter chairman, president and CEO Scott Garrett, and an eight-member executive committee of CEOs from in vitro diagnostics companies.
The new entity will focus on establishing a risk-based approach to regulating in vitro and reforming Medicare’s reimbursement system for clinical laboratory diagnostic tests.